A Phase 4 interventional study of Rifaximin in Severe Hepatic Impairment, sponsored by Bausch Health Americas, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-30.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to characterize the steady state plasma
The primary objective of this study is to characterize the steady state plasma PK of rifaximin (550 mg BID) in subjects with severe hepatic impairment (MELD 19 to 25 and MELD >25), as well as healthy subjects with normal hepatic function.
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rifaximin 550 mg BID
Drug: Rifaximin
Rifaximin 550 MG BID
Maximum Observed Plasma Concentration (Cmax)
Maximum observed plasma concentration (Cmax) of rifaximin and 25-desacetyl rifaximin, if measurable
Time frame: 7 days
Time of the Maximum Concentration (Tmax)
Time of the maximum concentration (Tmax) of rifaximin and 25-desacetyl rifaximin, if measurable
Time frame: 7 days
Area Under the Plasma Concentration Versus Time Curve (AUC) During the 12-hour Dose Interval
Area under the plasma concentration versus time curve (AUC) during the 12-hour dose interval of rifaximin and 25-desacetyl rifaximin, if measurable
Time frame: 7 days
| Milestone | Rifaximin |
|---|---|
| Started | 5 |
| Completed | 5 |
| Not completed | 0 |
Maximum observed plasma concentration (Cmax) of rifaximin and 25-desacetyl rifaximin, if measurable
| ng/mL | Rifaximin |
|---|---|
| rifaximin | 13.4 ± 90.0 |
| 25-desacetyl rifaximin | 0.356 ± 87.5 |
Time of the maximum concentration (Tmax) of rifaximin and 25-desacetyl rifaximin, if measurable
| hours | Rifaximin |
|---|---|
| rifaximin | 0.688 ± 0.688 |
| 25-desacetyl rifaximin | 0.625 ± 0.750 |
Area under the plasma concentration versus time curve (AUC) during the 12-hour dose interval of rifaximin and 25-desacetyl rifaximin, if measurable
| h*ng/mL | Rifaximin |
|---|---|
| rifaximin | 98.7 ± 107 |
| 25-desacetyl rifaximin | 3.04 ± 85.2 |
Collected over 7 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rifaximin | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Event | Rifaximin |
|---|---|
| VomitingGastrointestinal disorders | 1/5 |
| Tooth fractureInjury, poisoning and procedural complications | 1/5 |
| Age, Continuous(years) | Rifaximin |
|---|---|
| Mean | 45.8 ± 6.870 |
| Sex: Female, Male(Participants) | Rifaximin |
|---|---|
| Female | 3 |
| Male | 2 |
| Race (NIH/OMB)(Participants) | Rifaximin |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 5 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Model for End Stage Liver Disease Score at baseline: Healthy(Participants) | Rifaximin |
|---|---|
| Count of participants | 1 |
| Model for End Stage Liver Disease Score at baseline: 19 to 25(Participants) | Rifaximin |
|---|---|
| Count of participants | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jan 2019 to primary completion in Feb 2020, 12 months.
Results were first posted in Nov 2023, 3 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifaximin
Bausch Health Americas, Inc. →